Gout
Latest News
The earlier the better for colchicine post-MI: COLCOT
One substudy supported in-hospital initiation of colchicine and a second offered clues as to who may respond or experience tell-tale GI events.
Conference Coverage
LoDoCo2: Added steam for colchicine as secondary prevention
The benefits emerged early and continued to accrue through the trial, with no suggestion of attenuation during up to 5 years of treatment.
Conference Coverage
DECT has mixed performance in differentiating gout vs. CPPD
In a German cohort study of 30 patients, the noninvasive test had high specificity but only moderate to poor sensitivity.
Guidelines
EULAR gives pointers on intra-articular injection best practices
A task force based the recommendations on a systematic literature review and two surveys of health professionals and patients to help form expert...
Commentary
Advice on treating rheumatic diseases from a COVID-19 epicenter
Hospital for Special Surgery rheumatologists discuss their approach to caring for patients with rheumatic diseases within their practice during...
Guidelines
ACR gives guidance on rheumatic disease management during pandemic
When COVID-19 is suspected, rheumatic disease patients may continue their hydroxychloroquine but other rheumatic disease treatments may need to be...
Feature
Rheumatologists seek to reassure amid hydroxychloroquine shortage
Rheumatologists Jill P. Buyon and Peter M. Izmirly answer questions about the availability of hydroxychloroquine during the COVID-19 pandemic, and...
From the Journals
Cherry concentrate fails for gout flares
Gout patients given tart cherry concentrate over 28 days showed no differences in serum urate levels, compared with patients given placebo.
From the Journals
Gout rates reduced with SGLT2 inhibitors
Type 2 diabetes patients using SGLT2 inhibitors had significantly lower rates of gout than did those taking GLP1 agonists.
Guidelines
Updated gout guidelines: Don’t let kidney function dictate allopurinol dosing
Inadequate allopurinol dosing has been the bête noire of rheumatology for years.
Conference Coverage
Colchicine cut post-MI CVD events
PHILADELPHIA – Colchicine fulfilled the promise first seem in CANTOS that anti-inflammatory treatment can reduce cardiovascular disease events.